---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-035233"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T14:09:13.035315+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ionis Q2 revenue $225M (+20% YoY); operating loss narrows to $66M; key pipeline milestones

## Summary
- Total revenue $225M (up 20% YoY); loss from operations $66M vs $91M loss in Q2 2023; non-GAAP loss from ops $35M.
- WAINUA Q2 royalty revenue $4M; approved in Canada; U.S. launch progressing with AstraZeneca.
- Olezarsen NDA for FCS accepted for Priority Review, PDUFA Dec 19, 2024; Phase 3 sHTG studies fully enrolled, data H2:2025.
- Donidalorsen Phase 3 OASIS data published in NEJM; preparing U.S. NDA and EU MAA for HAE.
- Cash and short-term investments $2.1B; reaffirmed 2024 guidance; projects year-end cash $1.7B.

## SEC filing metadata
- accession: 0001140361-24-035233
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036124035233/0001140361-24-035233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036124035233/ef20033414_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-035233
- JSON: https://secwatch.observer/filing/0001140361-24-035233.json
- Plain text: https://secwatch.observer/filing/0001140361-24-035233.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.